相关实验视频

Updated: Sep 9, 2025

Role of Diffusion MRI Tractography in Endoscopic Endonasal Skull Base Surgery

Role of Diffusion MRI Tractography in Endoscopic Endonasal Skull Base Surgery

Published on: July 5, 2021

针对复发性和耐药性头瘤的向治疗:一个系统的叙述性审查

Yi Lin¹, Ning Luo¹, Bo Zhang¹

¹Department of Neurosurgery, Sanbo Brain Hospital, Capital Medical University, Beijing, China.

World neurosurgery

|August 30, 2025

概括

包括BRAF和MEK抑制剂在内的向分子治疗对乳头瘤 (PCP) 的治疗具有前景,特别是在减少瘤体积方面. 然而,由于不良事件和有限的长期数据,需要仔细监测.

科学领域:

癌症学
分子疗法
神经外科

背景情况:

乳头瘤 (PCP) 是一种罕见的脑瘤,对于复发或耐药病例的治疗选择有限.
有针对性的分子疗法,特别是BRAF和MEK抑制剂,已成为潜在的治疗方法.

研究的目的:

评估针对性分子治疗 (BRAF和MEK抑制剂) 的疗效和安全性,用于复发性和耐火性乳头瘤 (PCP).
探索这些抑制剂作为PCP新辅助治疗的潜力.

主要方法:

根据PRISMA指南进行系统和叙述性审查.
在使用BRAF和/ 或MEK抑制剂治疗PCP患者的临床研究中搜索了PubMed,EMBASE和Web of Science.
分析了57名患者的结局,包括瘤反应,存活率,不良反应和新辅助疗法的疗效.

主要成果:

特别是在混合类型的瘤中观察到显著的瘤体积减少 (78. 9% 的病例).
新辅助的BRAF- MEK抑制剂治疗在六个月内平均减少了88. 16%的瘤体积.
常见的不良反应 (发烧,皮疹,腹) 导致14. 5%的患者停止治疗;瘤形态显著影响治疗反应 (p<0. 05).

结论:

在降低PCP瘤体积方面,尤其是混合型瘤中,BRAF- MEK抑制剂显示出有希望的疗效.
副作用的高发病率和有限的长期随访需要对患者进行仔细监测.
需要进行更大规模的前性研究来确定PCP的最佳治疗方案.

关键词:

BRAF 抑制剂 MEK 抑制剂状瘤 (PCP)发生不良事件新辅助治疗针对性的治疗

更多相关视频

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Image-Guided Resection of Glioblastoma and Intracranial Implantation of Therapeutic Stem Cell-seeded Scaffolds

Image-Guided Resection of Glioblastoma and Intracranial Implantation of Therapeutic Stem Cell-seeded Scaffolds

Published on: July 16, 2018

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...